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1. Introduction
Gliomas, the most common primary brain tumors, are characterized by rapid proliferation,
marked infiltration, and poor prognosis and are known for their dismal outcomes (Iacob & Din‐
ca, 2009; Lefranc et al., 2006). The infiltrative nature of malignant glioma makes complete resec‐
tion  difficult,  as  tumor  margins  are  unclear.  Recurrence  of  glioma  takes  place  within
approximately 2 cm of the margins of the resected cavity owing to its invasive character (Aydin
et al., 2001; Wallner et al., 1989). The use of fluorescence to delineate tumor margins intraopera‐
tively has emerged as a safe and effective tool for increasing the extent of resection. Therefore,
methods that easily detect tumor margins during surgery would be extremely beneficial. 5-ami‐
nolevulinic acid (5-ALA) fluorescence-guided glioma resection is a rapidly growing, novel ap‐
proach to improve the extent of tumor resection with broad applications in both preclinical and
clinical settings (Stummer et al., 2000; Stummer et al., 1998b; Stummer et al., 1998c). Intraopera‐
tive tumor fluorescence provided by the chemical compound 5-ALA assists surgeons in identi‐
fying the true tumor margin during resection of glial neoplasms, consequently increasing the
extent of the resection. 5-ALA is the most studied fluorescer and has been used in many clinical
trials, including a multicenter phase III randomized controlled trial. Recent controlled Phase III
clinical trials have demonstrated that this surgical method enables more complete resection of
contrast-enhancing lesions than conventional microsurgery and improves progression-free
survival in patients with malignant glioma (Pichlmeier et al., 2008; Stummer et al., 2006).
Photodynamic therapy (PDT) is a treatment modality that takes advantage of the cytotoxic ef‐
fects induced by a photosensitizer and light in the presence of oxygen (Norum et al., 2009). This
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photodamage may be due to direct cytotoxicity, vascular damage, and inflammatory and im‐
munological responses (Castano et al., 2006). The relative importance of these pathways to the
therapeutic effects depends on the tissue oxygenation, photosensitizer formulation, distribu‐
tion, and light dosimeter (Norum et al., 2009). 5-ALA-induced protoporphyrin IX (PpIX) can al‐
so be used for 5-ALA-PDT rather than photodynamic diagnosis (PDD) by exposing the field to
either blue or red laser light; however, a red light at 632 nm would target a much larger tumor
volume owing to better light penetration (Eljamel et al., 2008). Activation of PpIX by red light in
combination with oxygen causes cell death by apoptosis and necrosis through the release of cy‐
totoxic singlet oxygen (Peng et al., 1997). This tool may aid in overcoming the hurdle of residual
tumor cells after traditional neurosurgery. Application of 5-ALA-PDT has been emerging as a
new field and is expected to create a major breakthrough in addressing several unsolved medi‐
cal issues, especially photokilling of residual neoplastic cells.
Developing technologies such as fluorescence operation-systems to enhance endogenous
fluorescence has fairly recently been shown to delineate brain tumor margins intraoperatively
(Babu & Adamson, 2012). 5-ALA fluorescence-guided resection shows great promise for
furthering our surgical abilities and will become the standard of care for patients diagnosed
with malignant glioma in the foreseeable future. The following review analyzes the recent
literature in an effort to describe how these modalities involving 5-ALA in glioma diagnostics
and therapy can and should be used in the treatment of patients with glioma. This article
reviews recent developments in the use of 5-ALA for simultaneous imaging and 5-ALA-
triggered photodamage in glioma patients (Figure 1).
2. General knowledge of 5–ALA
5-ALA (molecular weight, 167.6) is a natural biochemical precursor for heme synthesis in
living mammalian cells (Eljamel et al., 2008; Peng et al., 1997). Each cell metabolizes 5-ALA
along a set pathway toward heme production, inducing the synthesis of the endogenous flu‐
orescent molecule, PpIX, through metabolic conversion in the mitochondria (Bottomley &
Muller-Eberhard, 1988). When PpIX emits peak fluorescence at 635 nm with a peak excita‐
tion wavelength at 405 nm, it is observed as a red light through a filter that allows this
wavelength to pass. Clinical use of 5-ALA for PDT or PDD has also been reported in derma‐
tology, urology, neurosurgery, otorhinolaryngology, gynecology, and gastroenterology for
various epithelia and cancerous tissues (D'Hallewin et al., 1998; Guyon et al., 2012; Loning et
al., 2004; Piotrowski et al., 2004). In the USA, it has been used with the approval of the Food
and Drug Administration (FDA) as a therapeutic drug for solar keratosis. Its use has not yet
been approved by the pharmaceutical authority in Japan, and it is only used after obtaining
approval from the ethics committee of the respective institutes. The tumor tissue concentra‐
tion of the fluorescent dye peaks at 2–6 hours after oral administration and disappears by 12
hours. Administration of antacid should be avoided at the time of oral administration be‐
cause the dye is easily decomposed in the presence of alkali, and use of 5-ALA is contraindi‐
cated in cases of porphyria, a genetic disease. PpIX biosynthesized from 5-ALA is a
phototoxic substance, although the incidence of skin photosensitivity is lower than that re‐
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ported for conventional porphyrin derivatives (Stummer et al., 2006; Toda, 2008). When giv‐
en orally, 5-ALA has been shown to produce fluorescence in glial neoplasms both in vitro
and in vivo (Blake & Curnow, 2010). In addition, the fluorescence of PpIX is itself cytotoxic
and has the potential for use as an adjuvant photodynamic therapy for neoplastic tissue that
cannot be safely resected (Sherman et al., 2011). Since the administered 5-ALA is excreted
into the urine within 24 hours after oral administration and does not remain in the skin, the
occurrence of photosensitivity can be adequately prevented by avoiding sun exposure for
approximately 24 hours after administration.
Figure 1. Schematic representation of diagnostics and PDT of 5-ALA for glioma cells. The figure illustrates 5-ALA is
converted to PpIX in malignant gliomas via an oral-intake of exogenous 5-ALA. In the presence of an appropriate light
source with the specific wavelength, PpIX fluorescence acts bimodal function; fluorescence diagnostic marker and 5-
ALA-PDT. Red fluorescence acts as a discriminating marker to assist neurosurgeons to visualize the extent and margins
of tumors; 5-ALA-PDT results in a series of irreversible photochemical and photobiological events that cause directly
damage and killing glioma cells.
3. 5–ALA biology in glioma
5-ALA, the metabolic precursor of heme in the heme biosynthesis pathway, is not itself
fluorescent, but is metabolized into endogenous fluorescent PpIX (Gossner et al., 1998; Inoue
et al., 2007; Kennedy & Pottier, 1992; Loh et al., 1993; Peng et al., 1997). Heme biosynthesis
consists of a series of enzyme-catalyzed steps, involving 5-aminolevulinate synthases 1 and 2,
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5-aminolevulinate dehydratase, hydroxymethylbilane synthase, uroporphyrinogen III
synthase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase (CPOX), protopor‐
phyrinogen oxidase, and ferrochelatase (FECH). In addition to these enzymes, several
transporters are also involved in the biosynthesis and catabolism of heme and porphyrin,
including oligopeptide transporters 1 and 2 (PEPT1 and PEPT2) and the ABC transporters



































Figure 2. The porphyrin-heme biosynthetic pathway and putative mitochondrial transporters. The first step of heme
synthesis occurs in the mitochondrial matrix with the condensation of succinyl CoA and glycine by ALA synthase to
generate ALA. Oligopeptide transporters (PEPT1 or PEPT2) are responsible for the import of exogenous ALA from the
extracellular space into the cytoplasm of target cells. ALA is converted to coproporphyrinogen III by 4 enzymatic reac‐
tions. Then, coproporphyrinogen III is transported back into the mitochondrial intermembrane space (IMS), possibly
via ABCB6, where it is converted to protoporphyrinogen by protoporphyrinogen III oxidase. The conversion of proto‐
porphyrinogen to PpIX by protoporphyrinogen oxidase, its transport into the matrix and the addition of Fe2+ by ferro‐
chelatase (FECH) to generate heme are coupled processes. The transporter responsible for heme transfer across the
outer mitochondrial membrane remains unidentified. Heme formed from porphyrin is catabolized to biliverdin by the
microsomal enzyme heme oxygenase 1. Biliverdin is subsequently metabolized to bilirubin by biliverdin reductase.
ABCG2 transports porphyrins across the plasma membrane to maintain intracellular porphyrin homeostasis.
Porphyrins are synthesized from glycine and succinyl CoA via a series of enzymatic reactions.
The last enzymatic reaction is the conversion of PpIX to heme by FECH, which is located in
the inner mitochondrial membrane (Ferreira et al., 1995; Kemmner et al., 2008). Heme formed
from porphyrin is catabolized to biliverdin by the microsomal enzyme heme oxygenase 1.
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Subsequently, biliverdin is metabolized to bilirubin by biliverdin reductase. The PEPT1/PEPT2
(influx transporters) can transport exogenous ALA from the extracellular space into the
cytoplasm of target cells. ABCB6 is the ABC transporter responsible for the import of copro‐
porphyrinogen III into the mitochondria, whereas ABCG2 transports PpIX across the plasma
membrane to maintain intracellular PpIX homeostasis (Takahashi et al., 2011).
Oral-intake of 5-ALA results in the accumulation of PpIX in malignant gliomas. Because of the
presence of the blood-brain barrier (BBB), 5-ALA given via the oral route does not usually enter
the normal brain tissue. However, it can easily pass through the disrupted BBB found in the
glioma tissue (Stummer et al., 2003). PpIX that accumulates in the intracellular compartments
of tumor cells exhibits red fluorescence under excitation light of an appropriate wavelength
(Takahashi et al., 2011). PpIX-accumulating tumor cells can be visually discerned intraopera‐
tively from the surrounding normal cells that accumulate PpIX to a much lesser extent. To
date, little is known about the molecular mechanisms underlying PpIX accumulation in
malignant brain tumors after administration of 5-ALA; despite this, in the past decade, studies
on ALA focusing on the mechanism of 5-ALA uptake in glioma tissue have been conducted
by many research groups. Previously, our group revealed significantly greater down-regula‐
tion of FECH expression in glioblastomas than in normal brain tissues and that FECH plays a
role in the metabolism of 5-ALA in glioma (Teng et al., 2011). In addition, Takahashi et al.
demonstrated that the upregulated expression of the CPOX gene is correlated with the
intensity of tumor fluorescence induced by 5-ALA; they also found that the mRNA level of
ABCG2 was somewhat lower in the brain tumors with high ALA-induced fluorescence than
in those without ALA-induced fluorescence (Takahashi et al., 2011). Therefore, they assumed
that both the induction of the CPOX gene and the inhibition of ABCG2 would increase 5-ALA-
induced PpIX accumulation and thereby enhance the efficacy of 5-ALA-PDT in malignant
brain tumors. In agreement with this hypothesis, Zhao et al. demonstrated that ABCB6
expression levels were greatly elevated in human gliomas than in normal brain tissues and
correlated with glioma histologic grade, indicating a crucial role for ABCB6 in ALA metabo‐
lism and accumulation of PpIX in gliomas (Zhao et al., 2012).
Further studies are required to explore the detailed mechanism of 5-ALA uptake and improve
our knowledge concerning 5-ALA biology in gliomas.
4. 5–ALA guided neurosurgery
Many previous reports describing prognostic factors in patients with malignant gliomas
indicate that outcome is associated with the completeness of tumor removal (Stummer et al.,
1998a). Improving the prognosis of glioma patients cannot be achieved without considerable
effort to remove as much as of the lesion as possible. Since glioma tissue is not easily recognized
intraoperatively, methods that easily detect tumor margins during surgery would be extreme‐
ly beneficial. 5-ALA fluorescence-guided resection is a rapidly growing, novel approach in
treating glioma patients to improve the extent of tumor resection with broad applications in
both preclinical and clinical settings (Stummer et al., 2000; Stummer et al., 1998b; Stummer et
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al., 1998c). In 1998, Stummer et al. first presented a detailed description of the technical
principles for 5-ALA fluorescence-guided microsurgical resection of malignant glioma tissue
(Stummer et al., 1998a). Subsequently, they performed a prospective study in 52 glioblastoma
patients and identified the usefulness of 5-ALA-induced tumor fluorescence for guiding tumor
resection. Recent controlled Phase III clinical trials have demonstrated that compared to
conventional microsurgery, 5-ALA fluorescence-guided microsurgical resection enables more
complete resection of contrast-enhancing lesions and improves progression-free survival in
patients with malignant glioma (Pichlmeier et al., 2008; Stummer et al., 2006). After the rapid
development of the neurosurgical fluorescence operation microscope, several investigators
have recently demonstrated the feasibility of 5-ALA fluorescence-guided resection in patients
with glioma (Kuroiwa et al., 1998; Kuroiwa et al., 2001; Sherman et al., 2011). Widhalm et al.
also indicated that 5-ALA is a promising marker for intraoperative visualization of anaplastic
foci in diffusely infiltrating gliomas without contrast enhancement and showed that the
positive predictive value (PVV) of focal 5-ALA fluorescence for World Health Organization
(WHO) grade III glioma was 100% (sensitivity 89%) (Widhalm et al., 2010). In addition,
Nabavi’s group investigated the feasibility and selectivity of 5-ALA-induced fluorescence to
guide resection in recurrent gliomas (WHO grade III/IV) and found that 5-ALA fluorescence
(weak and strong) had a high PPV (97.2%) in all pathological-appearing tissues obtained from
354 biopsies performed in 36 patients (Nabavi et al., 2009). Based on these findings, they
suggested that 5-ALA fluorescence guidance is an effective surgical adjunct in the surgery of
recurrent malignant gliomas, and many other trials have displayed similar successful results
using 5-ALA fluorescence-guided resection in meningiomas to achieve optimal resection
(Coluccia et al., 2010; Kajimoto et al., 2007).
Despite the advantages of 5-ALA fluorescence, successful glioma resection often depends on
the neurosurgeon’s ability to distinguish residual tumor tissue from surrounding brain tissue
even with the assistance of PpIX fluorescence (Teng et al., 2011). The marginal area containing
infiltrating glioma cells shows vague fluorescence because the density of the glioma cells in
these areas is low and heterogeneous, resulting in insufficient 5-ALA uptake and PpIX
accumulation (Utsuki et al., 2006). Conversely, because of the presence of reactive astrocytes
and macrophages and leakage of PpIX into the extracellular matrix, false-positive (i.e., the area
fluoresced, but no tumor was seen histologically) results in weakly fluorescing normal-
appearing tissue are also common (Utsuki et al., 2007). Therefore, more objective and quanti‐
tative indicators need to be established for neurosurgeons to improve intraoperative
identification of tumor margins. Recently, a quantitative method involving spectroscopic
analysis for determining the amount of fluorescence present has been developed, which allows
more precise visualization of quantitative fluorescence from tumor tissues (Utsuki et al.,
2006; Valdes et al., 2011).
5. 5–ALA mediated-PDT
PDT is a tool for the treatment of certain cancerous and pre-cancerous conditions, especially
in the field of dermatology (Buytaert et al., 2007). Among the many kinds of photosensitizers,
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5-ALA has become widely accepted. 5-ALA-PDT is a novel treatment modality for early or
superficial cancers, as well as a palliative treatment to a certain extent, that triggers a photo‐
dynamic effect similar to that of light in the visible range to produce a rapid PDT response in
the targeted tissue. Three types of mechanisms have been identified in the literature as
contributing to the rapid PDT response in vivo: (1) PDT can directly damage and kill the
malignant tumor cells, either by apoptosis or a non-apoptotic mechanism; (2) PDT may
produce profound changes in the tumor vasculature, including blood flow stasis, vascular
collapse, and/or vascular leakage, that can result in indirect killing of malignant cells; and (3)
PDT can promote the release of cytokines and other inflammatory mediators from target cells
that induce an inflammatory response and recruit additional host cells to the tumor (Mac‐
Donald & Dougherty, 2001; Oleinick et al., 2002). Recent studies have shown that 5-ALA-PDT-
induced photodamage causes mitochondrial and nuclear DNA damage. As a result, massive
apoptosis occurs owing to mitochondrial release of cytochrome c and activation of caspase-3
and caspase-9 in glioma cells (Inoue et al., 2007; Karmakar et al., 2007). These results indicate
that 5-ALA-PDT triggers apoptosis through a mitochondrial pathway.
Compared to the other modalities, 5-ALA-PDT has the advantage of better specificity and
lower complication rates, and it is also a good alternative in tumor patients not eligible for
surgery. Unfortunately, current 5-ALA-PDT protocols have yet to be widely established in
clinical treatment for glioma. This may be partly due to limitations in current PDT regimens
and partly due to the therapeutic efficacy of 5-ALA-PDT in preclinical settings (Teng et al.,
2011). The reason for 5-ALA-PDT not being standard treatment in malignant glioma may be
multifactorial, including the lack of randomized controlled trials and an optimal 5-ALA-PDT
regimen. Generally, PDT efficacy depends on parameters such as the photosensitizing agent,
irradiance and timing, oxygen, photosensitizer concentration, and different pathologic grade
glioma tissue sensitivity to the PDT effect (Teng et al., 2011). Optimizing these parameters is
difficult, expensive, and time consuming. The efficacy of 5-ALA-PDT may also be limited by
reduced penetration of appropriate light through the target tissue and local acute phototoxicity
to normal surrounding brain tissue (Norum et al., 2009). In addition, post-treatment edema
and long-lasting skin photosensitivity after PDT of brain tumors are potentially challenging
side effects that neurosurgeons have to deal with. Regarding the specificity of PDD for glioma
surgery, new techniques allowing more specific accumulation of PpIX in target tumor cells
need to be developed. Further studies are required for screening available and specific glioma
antigens that are strongly expressed in glioma tissues, but not in normal brain tissues. 5-ALA
labeled with antibodies against glioma-specific antigens may be useful in increasing the
accumulation of PpIX and the specificity of PDD in glioma tissues. If the specificity and
selectivity of 5-ALA-PDT could be improved in glioma tissue, 5-ALA-PDT would certainly be
regarded as a promising and competitive alternative in glioma treatment.
6. Perspective
In this review, we focused on the 5-ALA agent as a potential treatment modality for patients
with malignant glioma. 5-ALA-induced fluorescence is a useful intraoperative tool for the
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visualization of glioma tissue, and 5-ALA-PDT is a promising and alternative adjuvant therapy
for photokilling residual neoplastic cells. Although impressive advances in the application of
5-ALA to glioma have been made from many clinical trials, this evolving field still faces
important challenges. For example, single imaging in solid malignant glioma tissue with all
of these features is not sufficient. Judgment of the extent of resection may still be treacherous
within infiltrating parts of brain tumors, where the ratio of background noise of normal brain
tissue to signal intensity of PpIX-saturated malignant glioma cells is less pronounced (Hefti et
al., 2012; Liao et al., 2012). Recent efforts to boost target-to-background ratios have used a
combination of intraoperative 5-ALA-induced fluorescence and 3D MRI imaging or neurona‐
vigation imaging with some success (Liao et al., 2008; Panciani et al., 2012). Furthermore, more
objective indicators to measure quantitative PpIX concentrations intraoperatively in the brain
tumor margin need to be established. In the future, laboratory and clinical studies should be
devoted to 5-ALA-PDT in conjunction with the use of other therapies, which will have maximal
effect on the residual tumor after resection. This multiple adjuvant therapy should enhance
specificity and allow lowering of the total PDT dose, while still increasing the therapeutic
efficacy of PDT. Other proposals should adjust the current PDT treatment regimens, modify
the existing photosensitizer, or develop new and more specific photosensitizers. Further
studies are needed to elucidate possible mechanisms of 5-ALA uptake that could explain the
diversity of intraoperative findings.
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